Joint (JYNT) Stock Price
Joint Price
Revenue has compounded at 25.8% per year over the past 13 years to 54.90 M USD. Earnings per share have grown at 22.8% per year over the last 12 years. Joint's net margin stands at 5.3%, down from 9.5% several years earlier. Analysts set a median price target of 9.18 USD, implying 10.3% above the current price. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 8% above its 52-week low.
Joint stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Joint over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Joint stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Joint's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Joint Price |
|---|---|
| 9/4/2026 | 8.32 USD |
| 9/3/2026 | 8.28 USD |
| 9/2/2026 | 8.24 USD |
| 9/1/2026 | 8.36 USD |
| 8/31/2026 | 8.44 USD |
| 8/30/2026 | 8.41 USD |
| 8/28/2026 | 8.44 USD |
| 8/27/2026 | 8.49 USD |
| 8/26/2026 | 8.54 USD |
| 8/25/2026 | 8.45 USD |
| 8/24/2026 | 8.48 USD |
| 8/21/2026 | 8.44 USD |
| 8/20/2026 | 8.25 USD |
| 8/19/2026 | 8.22 USD |
| 8/18/2026 | 8.62 USD |
| 8/17/2026 | 8.40 USD |
| 8/14/2026 | 8.45 USD |
| 8/13/2026 | 8.42 USD |
| 8/12/2026 | 8.55 USD |
| 8/10/2026 | 8.63 USD |
| 8/7/2026 | 8.33 USD |
| 8/6/2026 | 8.22 USD |
| 8/5/2026 | 8.32 USD |
| 8/4/2026 | 8.32 USD |
| 8/3/2026 | 8.21 USD |
| 7/31/2026 | 8.29 USD |
| 7/30/2026 | 8.37 USD |
| 7/29/2026 | 8.52 USD |
| 7/27/2026 | 8.52 USD |
| 7/23/2026 | 8.36 USD |
Joint Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Joint Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 7.00 | 13.00 | 20.00 | 25.00 | 31.00 | 48.00 | 58.00 | 80.00 | 101.00 | 46.00 | 52.00 | 54.00 | 60.00 | 62.00 | 67.00 |
| 150.00 | 40.00 | 85.71 | 53.85 | 25.00 | 24.00 | 54.84 | 20.83 | 37.93 | 26.25 | -54.46 | 13.04 | 3.85 | 11.11 | 3.33 | 8.06 |
| 60.00 | 57.14 | 84.62 | 85.00 | 84.00 | 87.10 | 87.50 | 89.66 | 90.00 | 91.09 | 78.26 | 76.92 | 79.63 | 79.63 | 79.63 | 79.63 |
| 3.00 | 4.00 | 11.00 | 17.00 | 21.00 | 27.00 | 42.00 | 52.00 | 72.00 | 92.00 | 36.00 | 40.00 | 43.00 | 47.78 | 49.37 | 53.35 |
| – | -1.00 | -9.00 | -15.00 | -3.00 | – | 3.00 | 5.00 | 6.00 | – | – | -1.00 | – | 4.00 | 7.00 | 5.00 |
| – | -14.29 | -69.23 | -75.00 | -12.00 | – | 6.25 | 8.62 | 7.50 | – | – | -1.92 | – | 6.67 | 11.29 | 7.46 |
| – | -3.00 | -8.00 | -15.00 | -3.00 | – | 3.00 | 13.00 | 7.00 | – | -9.00 | -5.00 | 2.00 | 3.00 | 5.00 | 4.00 |
| – | – | 166.67 | 87.50 | -80.00 | – | – | 333.33 | -46.15 | – | – | -44.44 | -140.00 | 50.00 | 66.67 | -20.00 |
| 9.17 | 7.33 | 10.83 | 12.81 | 13.59 | 14.10 | 14.54 | 14.72 | 14.95 | 14.82 | 14.75 | 14.96 | 14.58 | 14.58 | 14.58 | 14.58 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Joint generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Joint retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Joint's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Joint has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Joint's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Joint stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Joint Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Joint business model & stock analysis
Joint SWOT Analysis
Strengths
Joint Corp possesses several strengths that contribute to its competitive advantage in the market:
- Strong brand recognition and reputation in the industry
- Wide network of clinics and licensed chiropractors
- Effective marketing strategies to attract and retain clients
- Proprietary technology and software for streamlined operations
- Dedicated and experienced management team
Weaknesses
Despite its strengths, Joint Corp also faces certain weaknesses that can hinder its growth and performance:
- Dependence on third-party payers for a significant portion of revenue
- Limited international presence and potential growth opportunities
- Reliance on a single service offering (chiropractic care)
- Higher costs of operations compared to some competitors
- Vulnerability to changes in healthcare policies and regulations
Opportunities
Joint Corp can leverage several opportunities in the market to further enhance its position:
- Growing demand for non-invasive and drug-free healthcare alternatives
- Expansion into new geographic markets with underserved populations
- Development of strategic partnerships with insurance providers
- Integration of complementary wellness services to diversify offerings
- Utilization of telehealth technology for remote consultations
Threats
Several threats exist that could negatively impact Joint Corp's business and market position:
- Intense competition from both traditional healthcare providers and other alternative therapies
- Economic downturns and fluctuations affecting consumer spending on healthcare
- Increased regulatory scrutiny and potential legal challenges
- Negative public perception or misconceptions about chiropractic care
- Technological advancements enabling self-treatment options or substitutes
Joint Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Joint Segments
Joint Revenue by Segment (1/3)
3 Years
5 Years
10 Years
25 Years
Max
Details
Joint Revenue by Segment (2/3)
3 Years
5 Years
Max
Details
Joint Revenue by Segment (3/3)
3 Years
5 Years
Max
Details
Joint Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Joint historical P/E ratio, EBIT multiple, and P/S ratio
Joint annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Joint shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Joint forecasts and price targets in September 2026
Analyst Price Targets 2026Joint Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/8/2025 | Maintained | Buy | – | |
| 5/9/2025 | Maintained | Buy | – | |
| 11/8/2024 | Maintained | Buy | 55 | |
| 5/6/2024 | Maintained | Buy | – | |
| 5/3/2024 | Maintained | Buy | 55 | |
| 9/14/2023 | Maintained | Buy | 55 | |
| 8/11/2023 | Maintained | Buy | 55 | |
| 8/11/2023 | Downgrade | BuyHold | – | |
| 3/13/2023 | Upgrade | UnderperformNeutral | 55 | |
| 8/8/2022 | Maintained | Underperform | 55 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Joint Earnings Calls
Joint Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/6/2026 | 0.05USD | - | 14.86 MUSD | - | 2026 Q2 |
| 5/7/2026 | 0.03USD | - | 14.79 MUSD | - | 2026 Q1 |
| 3/12/2026 | 0.04USD | - | 14.30 MUSD | - | 2025 Q4 |
| 8/7/2025 | -0.02USD | - | 13.59 MUSD | - | 2025 Q2 |
| 11/7/2024 | 0.01USD | - | 28.94 MUSD | - | 2024 Q3 |
| 5/2/2024 | -USD | - | 30.12 MUSD | - | 2024 Q1 |
| 3/7/2024 | 0.01USD | - | 29.66 MUSD | - | 2023 Q4 |
| 8/2/2023 | 0.04USD | - | 30.66 MUSD | - | 2023 Q2 |
| 5/3/2023 | 0.02USD | - | 28.45 MUSD | - | 2023 Q1 |
| 2/22/2023 | 0.08USD | - | 27.58 MUSD | - | 2022 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Joint stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Joint shareholder structure
| % | Name |
|---|---|
26.01588% | |
5.91754% | |
3.92426% | |
3.68076% | |
2.21264% | |
1.90704% |
Joint Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
27.90% | SEC ↗ | |
27.90% | SEC ↗ | |
27.90% | SEC ↗ | |
23.60% | SEC ↗ | |
23.60% | SEC ↗ | |
19.50% | SEC ↗ | |
15.80% | SEC ↗ | |
15.40% | SEC ↗ | |
15.10% | SEC ↗ | |
12.93% | SEC ↗ |
Joint Executives and Management Board
14 members · avg. age 59 · 29 % women
Mr. Sanjiv Razdan (55)
President, Chief Executive Officer, Director · since 2024
864,235.00 USD
Management
Mr. Scott Bowman (58)
Chief Financial Officer
Mr. Ron Stilwell
Senior Vice President - Operations and Patient Experience
Mr. Charles Nelles
Chief Technology Officer
Ms. Debbie Gonzalez
Chief Marketing Officer
Mr. Steven Knauf
Vice President - Chiropractic and Compliance
Ms. Kirsten Chapman
Investor Relations
Board of Directors
Mr. Ronald DaVella (67)
Independent Director
Mr. Matthew Rubel (67)
Lead Independent Director
Mr. Abraham Hong (53)
Independent Director
Ms. Suzanne Decker (63)
Independent Director
Mr. Christopher Grandpre
Director
Ms. Sandi Karrmann
Director
Frequently asked questions about Joint
Joint Corp is primarily present in the United States.
The business model of Joint Corp primarily focuses on providing chiropractic care services. Joint Corp operates a network of chiropractic clinics across the United States, offering convenient and affordable access to chiropractic adjustments. Their model involves providing membership plans and walk-in options for individuals seeking chiropractic treatment for common health issues, including neck and back pain. Joint Corp's unique approach aims to offer standardized care through its proprietary software system, ensuring consistent treatment techniques across their clinics. By emphasizing a membership-based model, Joint Corp aims to create long-term relationships with their customers, enhancing accessibility and affordability for chiropractic care services.
Joint Corp is primarily active in the healthcare industry.
The main competitors of Joint Corp in the market include chiropractic clinics and wellness centers that offer similar services and treatments for musculoskeletal conditions. Some notable competitors include AmeriCare Physical Therapy, The Joint Chiropractic, and The Joint...the chiropractic place. These competitors, like Joint Corp, aim to provide quality chiropractic care and wellness solutions to their customers. However, Joint Corp stands out due to its unique business model of providing affordable and convenient chiropractic services through its nationwide network of franchised clinics.
The Joint Corp, founded in 1999, is a leading chiropractic care company based in Scottsdale, Arizona. With a mission to improve the quality of life through chiropractic care, the company operates over 600 clinics across the United States. Joint Corp provides convenient, affordable, and accessible chiropractic services, focusing on subluxation correction and wellness care. Over the years, the company has developed a reputation for its patient-centered approach, fostering long-term relationships with clients. With a strong commitment to promoting the benefits of chiropractic care, Joint Corp continues to expand its presence and deliver high-quality healthcare services to individuals seeking natural pain relief and improved mobility.
Joint Corp, a leading company in the chiropractic care industry, has achieved several significant milestones in its journey. Over the years, Joint Corp has successfully expanded its network of chiropractic clinics across the United States, providing accessible and high-quality care to thousands of patients. The company also went public in 2014, increasing its financial stability and allowing for further growth and innovation. Joint Corp has been recognized for its exceptional franchise model, attracting talented chiropractors to join its team and contribute to its success. Through strategic partnerships and continuous advancements in technology, Joint Corp continues to solidify its position as a trusted and pioneering name in the chiropractic care market.
The Joint Corp is a dynamic and innovative company that focuses on revolutionizing the chiropractic care industry. With a commitment to improving the quality of life for their patients, the Joint Corp values convenience, affordability, and accessibility. Their corporate philosophy revolves around providing exceptional chiropractic services that are easily accessible to individuals from all walks of life. By offering affordable pricing and eliminating the need for insurance, the Joint Corp aims to make chiropractic care a staple in everyone's wellness routine. Their dedication to patient satisfaction, superior service, and positive outcomes sets them apart in the healthcare industry.
Analysts currently set an average price target of 10.88 USD for the Joint stock (median: 9.18 USD), implying +34.5 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Joint stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Joint to generate revenue of 60.90 M USD and earnings per share of 0.25 USD.
Converted at the current exchange rate, the Joint share trades at 7.16 EUR (8.32 USD).
The Joint share (JYNT) is listed on 1 stock exchanges, including: NASDAQ (JYNT).
The company Joint Corp is a company specializing in the healthcare industry. With over 520 locations in the USA, the company is a leading provider of chiropractic services. The business model of Joint Corp is based on providing chiropractic services. The company offers a wide range of services to help people relieve their pain and discomfort. The services mainly focus on improving the mobility and function of the neck, back, shoulders, and other areas of the body. Joint Corp also offers various products to help alleviate painful symptoms. These include things like special pillows and sleep masks that help people sleep better. In addition, Joint Corp also offers dietary supplements that are intended to improve overall body health. The company also uses various marketing strategies to attract customers. These include digital marketing campaigns and marketing on social media. Joint Corp also collaborates with third-party partners and ensures that the staff in customer contact is friendly and courteous. The company seems to be successful as it is experiencing steady growth and successfully offers its services. Joint Corp has various divisions. The main business division is chiropractic services. In addition, the company is also involved in the healthcare products sector. Joint Corp also has a range of wellness and health programs. These programs are designed to help customers improve their mobility and function and promote their overall health. Joint Corp is a company dedicated to providing chiropractic services. It uses various marketing strategies to attract customers and offers a wide range of products to help people with pain and discomfort. In addition, Joint Corp offers various wellness and health programs. In summary, Joint Corp is a company dedicated to improving the health and well-being of its customers.
The expected revenue of Joint is 60.90 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Joint is 3.63 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Joint is currently 33.40. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Joint stock.
The price-to-sales ratio (P/S) of Joint is currently 1.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Joint stock.
The Eulerpool Quality Score for Joint is 2/10.
The ISIN of Joint is US47973J1025. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Joint is A12FCC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Joint is JYNT. The ticker symbol is used to trade Joint shares on the stock exchange.
Joint paid dividends every year for the past 0 years.
Joint is assigned to the 'Health' sector.
The dividends of Joint are distributed in USD.
Joint stock
Joint Peer Group
Joint Ticker
Joint FIGI
All fundamentals and in-depth analysis of Joint
Our stock analysis for Joint stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Joint. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.